Episode 4: Anti-IL-23 Medications and Durable Remission in Crohn's Disease Episode 4: Anti-IL-23 Medications and Durable Remission in Crohn's Disease
Drs Peter Higgins and Raja Atreya discuss the phenomenon of durable drug-free remission in certain patients with Crohn ' s disease and the future of intermittent induction and sequencing of therapies.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 21, 2022 Category: Consumer Health News Tags: Gastroenterology InDiscussion Source Type: news
Crohn's Disease vs. Ulcerative Colitis
Title: Crohn ' s Disease vs. Ulcerative ColitisCategory: Diseases and ConditionsCreated: 7/24/2017 12:00:00 AMLast Editorial Review: 7/8/2022 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - July 8, 2022 Category: Nutrition Source Type: news
Pearl Jam’s Mike McCready on first signs of ‘frightening’ bowel disease - ‘all this blood'
MANY rock stars have opened up about being an alcoholic, hooked on heroin, or plagued with mental health issues. But Pearl Jam's guitarist Mike McCready has opened up about something that is less commonly spoken about - coping with the unglamorous Crohn's disease and colitis. (Source: Daily Express - Health)
Source: Daily Express - Health - July 6, 2022 Category: Consumer Health News Source Type: news
What Eye Problems Are Associated With Crohn's Disease?
Title: What Eye Problems Are Associated With Crohn ' s Disease?Category: Diseases and ConditionsCreated: 7/1/2022 12:00:00 AMLast Editorial Review: 7/1/2022 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - July 1, 2022 Category: Nutrition Source Type: news
Monthly News Roundup - June 2022
Skyrizi Approved with On-Body Injector for Treatment of Crohn’s disease
Skyrizi (risankizumab-rzaa) works to reduce inflammation by binding to excess interleukin-23 (IL-23), a cytokine involved in several immune-mediated conditions. In June,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 30, 2022 Category: Pharmaceuticals Source Type: news
How Changing Your Diet Could Have a Major Impact on Managing Lupus Symptoms
After Jewell Singletary was diagnosed with lupus, she developed rheumatoid arthritis as well—a common pairing, since both are autoimmune conditions—and had to use a cane to navigate her college campus. When she graduated, the now 38-year-old New Jersey resident decided to be more focused on supporting her health, in an effort to maintain her mobility as she began her career.
She started in the kitchen.
First to be tossed were sugary drinks, fried foods, and highly processed options, she says. Once she eliminated them, it didn’t take long before she could discard one more important item: her cane.
[time-br...
Source: TIME: Health - June 29, 2022 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized Diet & Nutrition freelance healthscienceclimate Source Type: news
Episode 3: How Insurance Denials and Delays Affect Patients With Crohn's Episode 3: How Insurance Denials and Delays Affect Patients With Crohn's
Drs Peter Higgins and Frank Scott discuss the challenges of delays in care for patients with Crohn ' s disease, how insurance denials and delays harm patients, and what doctors can do to help.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 21, 2022 Category: Consumer Health News Tags: Gastroenterology InDiscussion Source Type: news
FDA Approves Skyrizi for Moderately to Severely Active Crohn Disease
MONDAY, June 20, 2022 -- Skyrizi (risankizumab-rzaa), an interleukin-23 inhibitor, has received U.S. Food and Drug Administration approval to treat moderately to severely active Crohn disease (CD) in adults, according to AbbVie.
Approved dosing for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 20, 2022 Category: Pharmaceuticals Source Type: news
MRI Index Can Predict Postop Recurrence in Crohn Disease
MONDAY, June 20, 2022 -- A magnetic resonance imaging (MRI) index has been developed and validated for predicting postoperative recurrence (POR) in Crohn disease (CD), according to a study published in the May issue of Clinical Gastroenterology and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 20, 2022 Category: Pharmaceuticals Source Type: news
FDA Approves Risankizumab (Skyrizi) for Crohn ’s Disease FDA Approves Risankizumab (Skyrizi) for Crohn ’s Disease
The approval is the third indication for the anti-interleukin 23 monoclonal antibody after approval for psoriatic arthritis earlier this year and plaque psoriasis in 2019.FDA Approvals (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - June 17, 2022 Category: Gastroenterology Tags: Gastroenterology News Alert Source Type: news
FDA OKs Risankizumab for Crohn's Disease
(MedPage Today) -- The FDA has approved risankizumab (Skyrizi), an interleukin (IL)-23 inhibitor, for the treatment of moderately to severely active Crohn's disease, AbbVie announced on Friday.
The approval for Crohn's disease was based on phase... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 17, 2022 Category: American Health Source Type: news
Skyrizi (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults
Third approved indication for Skyrizi (risankizumab-rzaa) is supported by safety and efficacy data from two induction and one maintenance clinical trials evaluating Skyrizi in moderately to severely active Crohn ' s disease, ADVANCE, MOTIVATE and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 17, 2022 Category: Drugs & Pharmacology Source Type: news
Two Biologics Work Equally Well for Active Crohn's Disease Two Biologics Work Equally Well for Active Crohn's Disease
For adults with moderate to severe Crohn ' s disease who have never been on a biologic agent, treatment with monotherapy with adalimumab or ustekinumab appear to be equally effective, according to results of the head-to-head SEAVUE trial.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - June 16, 2022 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Biologics for Crohn's Go Head to Head
(MedPage Today) -- Ustekinumab (Stelara) or adalimumab (Humira) were similarly effective as induction or maintenance therapy for moderate to severe Crohn's disease, according to the randomized SEAVUE trial.
In an intention-to-treat analysis involving... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 14, 2022 Category: Gastroenterology Source Type: news
Study Sees Strong Links Between Depression and Crohn's, Colitis
Researchers found that people with IBD were nine times more likely to develop depression than the general population, while their siblings who did not have IBD were nearly two times more likely to develop the mood disorder. (Source: WebMD Health)
Source: WebMD Health - June 6, 2022 Category: Consumer Health News Source Type: news
